GSGuisheng Song

Guisheng Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guisheng Song has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Clifford J. Steer

    Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA

    14 shared publications
  • Ningning Liu

    Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA

    7 shared publications
  • Tianpeng Zhang

    Department of Medicine, University of Minnesota, Minneapolis, USA

    7 shared publications
  • Heng Wu

    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN

    5 shared publications
  • Junjie Hu

    School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China; Center of Traditional Chinese Medicine Modernization for Liver Diseases, Hubei University of Chinese Medicine, Wuhan, 430065, China; Hubei Shizhen Laboratory, Wuhan, 430065, China

    4 shared publications
  • Xiaomei Wang

    Department of Hepatology,The First Hospital of Jilin University,Changchun,China

    4 shared publications

Latest Publications

  • Open Access

    SLC25A4 high Hepatocytes Enhance Lifestyle Intervention Response in MASLD by Recruiting Eating Macrophages

    by Yiting Qian, Linying Lai, Yu Zhang, Yan Meng, Ziping Song, Baoyuan Huang, Guisheng Song, Bo Sun, Wenzhuo Yang

    While lifestyle interventions (LSI) are the cornerstone of metabolic dysfunction‐associated steatotic liver disease (MASLD) management, the molecular mechanisms driving the histological and metabolic regression in LSI‐responsive patients remain unclear. C57BL/6N mice were hydrodynamically injected with Slc25a4 and Sleeping Beauty transposon . Single‐cell RNA sequencing (scRNA‐seq) profiled the hepatic immune landscape. Metabolomics and co‐culture assays analyzed intercellular crosstalk. Responsive MASLD patients had high SLC25A4 expression, correlating with exercise‐induced hepatic steatosis improvement. Slc25a4 overexpression augmented exercise effects. scRNA‐seq identified a distinct population of Clec4f + Timd4 + P2ry12 + macrophages, defined as lipid‐eating macrophages, in livers of Slc25a4 ‐overexpressing mice. Macrophage depletion reinstated hepatosteatosis in high‐fat, high‐fructose, and high‐cholesterol diet‐fed exercised mice with Slc25a4 overexpression. Mechanistically, SLC25A4 mediates mitochondrial ATP exchange and selective ATP efflux. Ectopically overexpressed Slc25a4 activates Pannexin 1 to release ATP, which recruits eating macrophages via P2ry12, clearing lipid‐laden hepatocytes. The GDF15‐PPARα axis between macrophages and hepatocytes was activated. Macrophage Gdf15 knockdown abrogated Slc25a4 ‐mediated enhanced hepatic fatty acid oxidation (FAO), and hepatic PPARα knockdown abolished this effect as well. Slc25a4 orchestrates an LSI‐responsive hepatocyte–macrophage axis: Pannexin 1‐mediated ATP release recruits lipid‐eating macrophages, whose GDF15 activates PPARα‐driven FAO, establishing Slc25a4 as a therapeutic target to restore exercise response in MASLD.

  • β-glucan nanotubes improve oral doxorubicin delivery for colorectal cancer by microbiota-mediated colon targeting and reduced toxicity

    by Ziwei Gao, Xiaoying Hou, Jun Tang, Yi Qin, Junjie Hu, Zhenpeng Qiu, Qi Wang, Cong Chang, Xinyan Chen, Zhaohua Shi, et al.


  • Open Access

    Causal association of social determinants of health with mortality and dynamic impact in patients with chronic heart failure: a longitudinal study using marginal structure models

    by Yujing Wang, Yongfeng Lv, Guisheng Song, Jingjing Yan, Yajing Wang, Yanbo Zhang, Jing Tian

    Aims: It is unclear whether there is a causal relationship between social determinants of health (SDoH) and mortality in patients with chronic heart failure (CHF). In this study, we assessed causality using inverse probability weighting (IPW) of marginal structural models (MSMs) during the course of CHF. Methods and results: A total of 1377 patients with CHF were enrolled in this multi-centre, prospective cohort study from September 2017 onwards. The social domain and two dimensions of the chronic heart failure patient-reported outcomes measure (CHF-PROM) were used to assess SDoH, social support, and support utilization in these patients. CHF-PROM and mortality information were obtained at 1, 3, and 6 months following discharge and every 6 months thereafter at regular follow-up visits. The impact of SDoH, social support, and support utilization on mortality was analysed by logistic regression and IPW of MSMs. Logistic regression showed that SDoH, social support, and support utilization at baseline were not associated with mortality. After adjustment for confounders, MSMs showed that SDoH and social support were not associated with mortality at baseline. In contrast, low support utilization at baseline and unfavourable SDoH, low social support, and low support utilization during follow-up increased the risk of death. Conclusion: Using follow-up data and analysis of MSMs, we found that long-term out-of-hospital effects of SDoH, but not one-time effects, were risk factors for mortality in patients with CHF. SDoH should be assessed during the entire course of CHF to prolong patient survival. Registration: Chinese Clinical Trial Registry, ChiCTR2100043337 (https://www.chictr.org.cn/showproj.html?proj=64980).


  • Cracking HCC: Targeting diacylglycerol kinase eta to tackle therapy resistance and cancer stemness

    by Guisheng Song

    An abstract is unavailable. This article is available as a PDF only.

  • miRNAs in HCC, pathogenesis, and targets

    by Guisheng Song, Xiaofan Yu, Hongtao Shi, Bo Sun, Stuart Amateau

    Liver cancer is the third leading cause of cancer-related mortality worldwide. HCC, the most common type of primary liver cancer, is driven by complex genetic, epigenetic, and environmental factors. MicroRNAs, a class of naturally occurring small noncoding RNAs, play crucial roles in HCC by simultaneously modulating the expression of multiple genes in a fine-tuning manner. Significant progress has been made in understanding how miRNAs influence key oncogenic pathways, including cell proliferation, apoptosis, angiogenesis, and epithelial-mesenchymal transition (EMT), as well as their role in modulating the immune microenvironment in HCC. Due to the unexpected stability of miRNAs in the blood and fixed HCC tumors, recent advancements also highlight their potential as noninvasive diagnostic tools. Restoring or inhibiting specific miRNAs has offered promising strategies for targeted HCC treatment by suppressing malignant hepatocyte growth and enhancing antitumor immunity. In this comprehensive review, we consolidate previous research and provide the latest insights into how miRNAs regulate HCC and their therapeutic and diagnostic potential. We delve into the dysregulation of miRNA biogenesis in HCC, the roles of miRNAs in the proliferation and apoptosis of malignant hepatocytes, angiogenesis and metastasis of HCC, the immune microenvironment in HCC, and drug resistance. We also discuss the therapeutic and diagnostic potential of miRNAs and delivery approaches of miRNA drugs to overcome the limitations of current HCC treatment options. By thoroughly summarizing the roles of miRNAs in HCC, our goal is to advance the development of effective therapeutic drugs with minimal adverse effects and to establish precise tools for early diagnosis of HCC.


  • Open Access

    MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice

    by Chao Li, Jing Tian, Ningning Liu, David Song, Clifford J. Steer, Qinghua Han, Guisheng Song


  • MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux

    by Ningning Liu, Jing Tian, Clifford J. Steer, Qinghua Han, Guisheng Song

    Background and Aims: Hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia are interconnected metabolic disorders. This study is designed to characterize how microRNA-206-3p (miR-206) simultaneously prevents de novo lipogenesis (DNL), cholesterol synthesis, and VLDL production in hepatocytes while promoting cholesterol efflux in macrophages. Approach and Results: MiR-206 levels were reduced in hepatocytes and macrophages of mice subjected to a high-fat, high-cholesterol diet. A negative feedback between LXRα (liver X receptor alpha) and miR-206 is formed to maintain high LXRα and low miR-206 in hepatocytes. Systemic administration of miR-206 alleviated hepatosteatosis, hypertriglyceridemia, and hypercholesterolemia in mice. A significant reduction in LDL cholesterol and VLDL cholesterol but unaltered HDL cholesterol was observed in miR-206-treated mice. Mirroring these findings, miR-206 reprogrammed the transcriptome of hepatocytes towards the inhibition of DNL, cholesterol synthesis, and assembly and secretion of VLDL. In macrophages, miR-206 activated the expression of genes regulating cholesterol efflux. Hepatocyte-specific expression of miR-206 reduced hepatic and circulating triglycerides and cholesterol, as well as VLDL production, while transplantation of macrophages bearing miR-206 facilitated cholesterol efflux. Mechanistically, miR-206 directly targeted Lxrα and Hmgcr in hepatocytes but facilitated expression of Lxrα in macrophages by targeting macrophage-specific tricho-rhino-phalangeal syndrome 1 (TRPS1), a transcription repressor of Lxrα. By targeting Hmgcr and Lxrα, miR-206 inhibited DNL, VLDL production, and cholesterol synthesis in hepatocytes, whereas it drove cholesterol efflux by activating the TRPS1-LXRα axis. Conclusions: MiR-206, through differentially modulating LXRα signaling in hepatocytes and macrophages, inhibits DNL, promotes cholesterol efflux, and concurrently hinders cholesterol synthesis and VLDL production. MiR-206 simulates the functions of lipid-lowering medications, statins, and LXRα agonists.


  • Open Access

    A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma

    by Junjie Hu, Ningning Liu, David Song, Clifford J. Steer, Guohua Zheng, Guisheng Song

    Hepatic cholesterol accumulation and hypercholesterolemia are implicated in hepatocellular carcinoma (HCC). However, the therapeutic effects of cholesterol-lowering drugs on HCC are controversial, indicating that the relationship between cholesterol metabolism and HCC is more complex than anticipated. A positive feedback between cholesterol synthesis and the pentose phosphate pathway (PPP) rather than glycolysis was formed in tumors of c-Myc mice. Blocking the PPP prevented cholesterol synthesis and thereby HCC in c-Myc mice, while ablating glycolysis did not affect cholesterol synthesis and failed to prevent c-Myc-induced HCC. Unexpectedly, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) and G6PD (glucose-6-phosphate dehydrogenase), the rate-limiting enzymes of cholesterol synthesis and the PPP, were identified as direct targets of microRNA-206. By targeting Hmgcr and G6pd, microRNA-206 disrupted the positive feedback and fully prevented HCC in c-Myc mice, while 100% of control mice died of HCC. Disrupting the interaction of microRNA-206 with Hmgcr and G6pd restored cholesterol synthesis, the PPP and HCC growth that was inhibited by miR-206. This study identified a previously undescribed positive feedback loop between cholesterol synthesis and the PPP, which drives HCC, while microRNA-206 prevents HCC by disrupting this loop. Cholesterol synthesis as a process rather than cholesterol itself is the major contributor of HCC.


  • Open Access

    A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma

    by Guisheng Song, Junjie Hu, Ningning Liu, David Song, Clifford Steer, Guohua Zheng

    Hepatic cholesterol accumulation and hypercholesterolemia are implicated in hepatocellular carcinoma (HCC). However, the therapeutic effects of cholesterol lowering drugs on HCC are controversial, indicating that the relationship between cholesterol metabolism and HCC is more complex than anticipated. A positive feedback between cholesterol synthesis and the pentose phosphate pathway (PPP) rather than glycolysis was formed in tumors of c-Myc mice. Blocking the PPP prevented inhibited cholesterol synthesis and thereby HCC in c-Myc mice, while ablating glycolysis did not affect cholesterol synthesis and failed to prevent c-Myc-induced HCC. Unexpectedly, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) and G6PD (glucose-6-phosphate dehydrogenase), the rate-limiting enzymes of cholesterol synthesis and the PPP, were identified as direct targets of microRNA-206. By targeting Hmgcr and G6pd, microRNA-206 disrupted the positive feedback and fully prevented HCC in c-Myc mice, while 100% of control mice dies of HCC. Disrupting the interaction of microRNA-206 with Hmgcr and G6pd restored cholesterol synthesis, the PPP and HCC growth that was inhibited by miR-206. Conclusions: This study identified a previously undescribed positive feedback loop between cholesterol synthesis and the PPP, which drives HCC, while microRNA-206 prevents HCC by disrupting this loop. Cholesterol synthesis as a process rather than cholesterol itself is the major contributor of HCC.